Table 1.
Demographic, clinical and treatment-related data of the study cohort
| Variables | COX-2 (+) n=81 | COX-2 (−) n=136 | Total n=217 | p |
|---|---|---|---|---|
| Gender; n (%) | ||||
| Female | 79 (98) | 134 (99) | 213 (98) | 0.60 |
| Male | 2 (2) | 2 (1) | 4 (2) | |
| Age; median year (SD) | 56 (11.9) | 57 (13.03) | 56 (12.6) | 0.82 |
| Operation; n (%) | ||||
| Lumpectomy | 32 (40) | 52 (38) | 84 (39) | 0.72 |
| Mastectomy | 49 (60) | 84 (62) | 133 (61) | |
| Axillary technique; n (%) | ||||
| Only sentinel node biopsy | 22 (27) | 43 (32) | 65 (30) | 0.50 |
| Axillary dissection | 59 (73) | 93 (68) | 152 (70) | |
| Radiotherapy; n (%) | ||||
| No | 37 (46) | 55 (40) | 92 (42) | 0.50 |
| Yes | 44 (54) | 81 (60) | 125 (58) | |
| Chemotherapy; n (%) | ||||
| No | 29 (36) | 55 (40) | 84 (39) | 0.50 |
| Yes | 52 (64) | 81 (60) | 133 (61) | |
| Hormonotherapy; n (%) | ||||
| No | 29 (36) | 34 (25) | 63 (29) | 0.10 |
| Yes | 52 (64) | 102 (75) | 154 (71) | |
| Trastuzumab; n (%) | ||||
| No | 69 (85) | 127 (93) | 196 (90) | 0.04 |
| Yes | 12 (15) | 9 (7) | 21 (10) | |
| Histopathologic type; n (%) | ||||
| Invasive lobular cancer | 2 (2) | 9 (7) | 11 (5) | 0.20 |
| Invasive ductal cancer | 73 (91) | 115 (84) | 188 (87) | |
| Invasive mixed cancer | 4 (5) | 11 (8) | 15 (7) | |
| Others | 2 (2) | 1 (1) | 3 (1) | |
| Tumor size; mean mm. (SD) | 25 (12.4) | 28 (17.4) | 27 (15.8) | 0.10 |
| Tumor size; n (%) | ||||
| T1 | 28 (34) | 49 (36) | 77 (35) | 0.20 |
| T2 | 50 (62) | 73 (54) | 123 (57) | |
| T3 | 3 (4) | 14 (10) | 17 (8) | |
| Histologic grade; n (%) | ||||
| I | 12 (15) | 19 (14) | 31 (14) | 0.70 |
| II | 41 (51) | 77 (57) | 118 (54) | |
| III | 28 (34) | 40 (29) | 68 (32) | |
| Axillary stage; n (%) | ||||
| N0 | 48 (59) | 63 (46) | 111 (51) | 0.13 |
| N1 | 22 (27) | 43 (32) | 65 (30) | |
| N2 | 10 (13) | 21 (15) | 31 (14) | |
| N3 | 1 (1) | 9 (7) | 10 (5) | |
| Pathological stage; n (%) | ||||
| Stage 1 | 24 (30) | 30 (22) | 54 (25) | 0.20 |
| Stage 2 | 45 (56) | 74 (54) | 119 (55) | |
| Stage 3 | 12 (14) | 32 (24) | 44 (20) | |
| ER; n (%) | ||||
| Negative | 21 (26) | 27 (20) | 48 (22) | 0.30 |
| Positive | 60 (74) | 109 (80) | 169 (78) | |
| PR; n (%) | ||||
| Negative | 32 (40) | 42 (31) | 74 (34) | 0.20 |
| Positive | 49 (60) | 94 (69) | 143 (66) | |
| HER2/neu; n (%) | ||||
| Negative | 55 (68) | 111 (82) | 166 (76) | 0.07 |
| Positive | 14 (17) | 14 (10) | 28 (13) | |
| Undetermined | 12 (15) | 11 (8) | 23 (11) | |
| Ki67 index; n (%) | ||||
| Low | 29 (36) | 71 (52) | 100 (46) | 0.02 |
| High | 52 (64) | 65 (48) | 117 (54) | |
| Molecular subtype; n (%) | ||||
| Luminal A type | 46 (57) | 94 (69) | 140 (64) | 0.24 |
| Luminal B type | 8 (10) | 7 (5) | 15 (7) | |
| HER2/neu type | 6 (7) | 7 (5) | 13 (6) | |
| Basal like type | 9 (11) | 17 (13) | 26 (12) | |
| Undetermined | 12 (15) | 11 (8) | 23 (11) |
COX-2: Cyclooxygenase-2; SD: standard deviation; ER: Estrogen receptor; PR: progesterone receptor